Zacks Research Downgrades Collegium Pharmaceutical (NASDAQ:COLL) to Hold

Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other research firms also recently weighed in on COLL. Weiss Ratings restated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. Wall Street Zen cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Finally, Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $57.50.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $36.29 on Tuesday. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71. The stock has a market capitalization of $1.18 billion, a PE ratio of 17.79 and a beta of 0.73. Collegium Pharmaceutical has a fifty-two week low of $29.19 and a fifty-two week high of $50.79. The company has a fifty day moving average of $34.78 and a two-hundred day moving average of $37.64.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm had revenue of $193.52 million for the quarter, compared to analyst estimates of $184.47 million. During the same period last year, the company posted $1.49 EPS. Collegium Pharmaceutical’s quarterly revenue was up 8.9% compared to the same quarter last year. As a group, research analysts forecast that Collegium Pharmaceutical will post 6.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Collegium Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock worth $104,465,000 after purchasing an additional 29,876 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of Collegium Pharmaceutical by 65.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock valued at $60,776,000 after buying an additional 518,721 shares during the period. Louisiana State Employees Retirement System purchased a new stake in shares of Collegium Pharmaceutical in the 1st quarter valued at approximately $463,000. Jackson Creek Investment Advisors LLC increased its holdings in shares of Collegium Pharmaceutical by 263.9% during the 4th quarter. Jackson Creek Investment Advisors LLC now owns 38,846 shares of the specialty pharmaceutical company’s stock worth $1,799,000 after buying an additional 28,170 shares during the last quarter. Finally, Intech Investment Management LLC increased its holdings in shares of Collegium Pharmaceutical by 25.5% during the 4th quarter. Intech Investment Management LLC now owns 108,855 shares of the specialty pharmaceutical company’s stock worth $5,040,000 after buying an additional 22,146 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.